Filtered By:
Condition: Bleeding
Management: Funding
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 37 results found since Jan 2013.
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
Publication date: Available online 5 November 2015 Source:The Lancet Author(s): A Michael Lincoff, Roxana Mehran, Thomas J Povsic, Steven L Zelenkofske, Zhen Huang, Paul W Armstrong, P Gabriel Steg, Christoph Bode, Mauricio G Cohen, Christopher Buller, Peep Laanmets, Marco Valgimigli, Toomas Marandi, Viliam Fridrich, Warren J Cantor, Bela Merkely, Jose Lopez-Sendon, Jan H Cornel, Jaroslaw D Kasprzak, Michael Aschermann, Victor Guetta, Joao Morais, Peter R Sinnaeve, Kurt Huber, Rod Stables, Mary Ann Sellers, Marilyn Borgman, Lauren Glenn, Arnold I Levinson, Renato D Lopes, Vic Hasselblad, Ri...
Source: The Lancet - November 6, 2015 Category: Journals (General) Source Type: research
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial
Publication date: Available online 16 March 2015 Source:The Lancet Author(s): Marco Valgimigli , Andrea Gagnor , Paolo Calabró , Enrico Frigoli , Sergio Leonardi , Tiziana Zaro , Paolo Rubartelli , Carlo Briguori , Giuseppe Andò , Alessandra Repetto , Ugo Limbruno , Bernardo Cortese , Paolo Sganzerla , Alessandro Lupi , Mario Galli , Salvatore Colangelo , Salvatore Ierna , Arturo Ausiello , Patrizia Presbitero , Gennaro Sardella , Ferdinando Varbella , Giovanni Esposito , Andrea Santarelli , Simone Tresoldi , Marco Nazzaro , Antonio Zingarelli , Nicoletta de Cesare , Stefano Rigattieri , Paolo Tosi , Cataldo Palmieri ,...
Source: The Lancet - March 17, 2015 Category: Journals (General) Source Type: research
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Publication date: Available online 11 March 2015 Source:The Lancet Author(s): Christian T Ruff , Robert P Giugliano , Eugene Braunwald , David A Morrow , Sabina A Murphy , Julia F Kuder , Naveen Deenadayalu , Petr Jarolim , Joshua Betcher , Minggao Shi , Karen Brown , Indravadan Patel , Michele Mercuri , Elliott M Antman Background New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vitamin K antagonists. A concern has emerged, however, that measurement of drug concentration or ...
Source: The Lancet - March 12, 2015 Category: Journals (General) Source Type: research
Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial
Publication date: Available online 12 February 2015 Source:The Lancet Neurology Background Extracranial carotid and vertebral artery dissection is an important cause of stroke, especially in young people. In some observational studies it has been associated with a high risk of recurrent stroke. Both antiplatelet drugs and anticoagulant drugs are used to reduce risk of stroke but whether one treatment strategy is more effective than the other is unknown. We compared their efficacy in the Cervical Artery Dissection in Stroke Study (CADISS), with the additional aim of establishing the true risk of recurrent stroke. Methods W...
Source: The Lancet Neurology - February 13, 2015 Category: Neurology Source Type: research
Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) trial
DiscussionThis paper and attachment describe the trial's statistical analysis plan, as developed from the protocol during recruitment and prior to unblinding of data. The statistical analysis plan contains design and methods for analyses, and unpopulated tables and figures for the primary and baseline publications. The data from the trial will provide the first large‐scale randomized evidence for the use of intensive antiplatelet therapy for preventing recurrence after acute stroke and transient ischemic attack.
Source: International Journal of Stroke - December 31, 2014 Category: Neurology Authors: Philip M. W. Bath, Katie Robson, Lisa J. Woodhouse, Nikola Sprigg, Robert Dineen, Stuart Pocock, Tags: Protocol Source Type: research
Quick magnesium treatment fails to improve stroke outcomes, but study has silver lining
In the first study of its kind, a consortium led by UCLA physicians found that giving stroke patients intravenous magnesium within an hour of the onset of symptoms does not improve stroke outcomes.
However, the 8-year trial did find that with the help of paramedics in the field, intravenous medications can frequently be administered to stroke victims within that so-called "golden hour," during which they have the best chance to survive and avoid debilitating, long-term neurological damage.
The latter finding is a "game-changer," said Dr. Jeffrey Saver, director of the UCLA Stroke Center and a professor of ...
Source: UCLA Newsroom: Health Sciences - February 13, 2014 Category: Universities & Medical Training Source Type: news
Funding For 'Holy Grail' Of Anticoagulant Drugs, University Of Cambridge
XO1 Ltd, a University of Cambridge and Addenbrooke's Hospital spin-out company, has raised $11 million in funding to develop a new anticoagulant medication which prevents stroke and heart attacks without causing bleeding. The company explained that the new drug, a synthetic antibody called Ichorcumab, has the potential to save millions of lives. Funding for the Ichorcumab research came from Index Ventures, a life science investor...
Source: Health News from Medical News Today - June 17, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news
